Nidal Morrar, MD
Family Medicine · Foley, ALNPI 1952382038
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.3% of the total across 197 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 23.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2020 at $1,661 and has fallen 86.4% since, to $226 in 2025.
Across 197 payments — averaging $32.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- AbbVie$910
- Pfizer$449
- Novo Nordisk$428
- Lilly USA, LLC$332
- Sanofi-aventis U.S. LLC$316
- plus $2K from 27 others
Across 506 payments — averaging $5994.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$1.3M
- Novartis$880K
- Chiesi USA, Inc.$342K
- GSK$184K
- Romark Laboratories, LC$111K
- AstraZeneca$86K
- plus $132K from 4 others
What the payments were for
- Speaking & faculty fees$3105%
- Food & beverage$5,97494%
- Education$521%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 20 | $1,510 |
| AbbVie(2 entities) | 51 | $910 |
| Pfizer | 19 | $449 |
| Novo Nordisk | 17 | $428 |
| Lilly USA, LLC | 17 | $332 |
| Sanofi-aventis U.S. LLC | 5 | $316 |
| Paratek Pharmaceuticals, Inc. | 6 | $312 |
| Johnson & Johnson | 6 | $265 |
| GSK | 3 | $217 |
| Bayer | 2 | $187 |
| Eisai Inc. | 4 | $169 |
| Esperion Therapeutics, Inc. | 3 | $156 |
| Amarin Pharma, Inc. | 16 | $155 |
| Amgen | 1 | $125 |
| Jazz Pharmaceuticals Inc. | 1 | $123 |
| Radius Health, Inc. | 1 | $114 |
| Medtronic | 1 | $92 |
| Otsuka America Pharmaceutical, Inc. | 3 | $67 |
| Sanofi | 1 | $60 |
| Merck | 1 | $53 |
| Kowa Pharmaceuticals America, Inc. | 4 | $53 |
| Supernus Pharmaceuticals, Inc. | 3 | $47 |
| Endo Pharmaceuticals Inc. | 2 | $47 |
| Boehringer Ingelheim | 1 | $18 |
| Optinose US, Inc. | 1 | $16 |
| Exact Sciences | 1 | $16 |
| Shield Therapeutics Inc | 1 | $16 |
| Daiichi Sankyo Inc. | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Boston Scientific | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| Mylan Specialty L.p. | 1 | $13 |
| Axsome Therapeutics, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,336 in reported general payments places this provider in the 85th percentile of 1,680 family medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 85 | $98,280 |
| EliquisApixaban | 116 | $96,696 |
| JardianceEmpagliflozin | 84 | $84,053 |
| JanuviaSitagliptin Phosphate | 71 | $67,149 |
| TrulicityDulaglutide | 45 | $54,765 |
| FarxigaDapagliflozin Propanediol | 71 | $54,288 |
| MounjaroTirzepatide | 33 | $35,247 |
| XareltoRivaroxaban | 35 | $21,422 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 28 | $18,590 |
| EntrestoSacubitril/Valsartan | 21 | $15,633 |
| Bydureon BciseExenatide Microspheres | 13 | $10,298 |
| DapagliflozinDapagliflozin Propanediol | 21 | $5,212 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 55 | $5,092 |
| Omeprazole | 272 | $4,546 |
| Levothyroxine Sodium | 434 | $4,240 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $428 | $98,28085 claims |
| PfizerEliquis | $449 | $96,696116 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $332 | $90,01278 claims |
| Boehringer IngelheimJardiance | $18 | $84,05384 claims |
| MerckJanuvia | $53 | $67,14971 claims |
| AstraZenecaFarxiga | $1,510 | $54,28871 claims |
| Johnson & JohnsonXarelto | $265 | $21,42235 claims |
| GSKTrelegy Ellipta | $217 | $18,59028 claims |
| AbbVieSynthroid | $910 | $2,21627 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,680 family medicine providers in Alabama.
Other family medicine in Foley
- Eric CheungFoley$20K
- Lashelle BarmoreBirmingham$486K
- Regina BenjaminBayou la Batre$222K
- Jonathan ParkerMuscle Shoals$214K
- Kathleen DupperHuntsville$210K
- Whitney TewHuntsville$114K
- Kelly HunterTuscaloosa$84K
- Daniel EnglertHuntsville$82K
- Joel LaughlinMobile$75K
- Ashleigh Butts-WilkersonMobile$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.